{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:41:20Z","timestamp":1793148080609,"version":"4.5.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,5,13]],"date-time":"2027-05-13T00:00:00Z","timestamp":1810166400000},"content-version":"am","delay-in-days":346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007914","name":"University of Texas Southwestern Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R25MH101078"],"award-info":[{"award-number":["R25MH101078"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH126202"],"award-info":[{"award-number":["MH126202"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.biopsych.2025.11.009","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:49:47Z","timestamp":1763765387000},"page":"1025-1051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Lessons From Clinical Trials of Immunomodulatory Drugs in Psychiatric Disorders"],"prefix":"10.1016","volume":"99","author":[{"given":"Thomas","family":"Pak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabila","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2764-2391","authenticated-orcid":false,"given":"Manish K.","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2025.11.009_bib1","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","article-title":"Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States","volume":"75","author":"Hasin","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib2","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2025.11.009_bib3","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR\u2217D Report","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/0706743716659417","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological treatments","volume":"61","author":"Kennedy","year":"2016","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nri.2015.5","article-title":"The role of inflammation in depression: From evolutionary imperative to modern treatment target","volume":"16","author":"Miller","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.biopsych.2025.11.009_bib6","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/946813","article-title":"Role of prostaglandins in neuroinflammatory and neurodegenerative diseases","volume":"2012","author":"Lima","year":"2012","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.biopsych.2025.11.009_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1130989","article-title":"Chronic stress, neuroinflammation, and depression: An overview of pathophysiological mechanisms and emerging anti-inflammatories","volume":"14","author":"Hassamal","year":"2023","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib8","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1096\/fj.09-141978","article-title":"Cellular mechanisms of IL-17-induced blood-brain barrier disruption","volume":"24","author":"Huppert","year":"2010","journal-title":"FASEB J"},{"key":"10.1016\/j.biopsych.2025.11.009_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12974-016-0513-y","article-title":"Sustained TNF production by central nervous system infiltrating macrophages promotes progressive autoimmune encephalomyelitis","volume":"13","author":"Valentin-Torres","year":"2016","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.biopsych.2025.11.009_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2024.167479","article-title":"25-hydroxycholesterol attenuates tumor necrosis factor alpha-induced blood-brain barrier breakdown in vitro","volume":"1870","author":"Loiola","year":"2024","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.biopsych.2025.11.009_bib11","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/s41380-018-0096-3","article-title":"What does plasma CRP tell us about peripheral and central inflammation in depression?","volume":"25","author":"Felger","year":"2020","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib12","doi-asserted-by":"crossref","first-page":"16136","DOI":"10.1073\/pnas.1415191111","article-title":"Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress","volume":"111","author":"Hodes","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2025.11.009_bib13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41467-017-02794-5","article-title":"Epigenetic modulation of inflammation and synaptic plasticity promotes resilience against stress in mice","volume":"9","author":"Wang","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.biopsych.2025.11.009_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psyneuen.2018.05.017","article-title":"Association of T and non-T cell cytokines with anhedonia: Role of gender differences","volume":"95","author":"Jha","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.biopsych.2025.11.009_bib15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.bbi.2017.02.020","article-title":"Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression","volume":"62","author":"K\u00f6hler-Forsberg","year":"2017","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.biopsych.2025.11.009_bib16","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.bbi.2016.03.012","article-title":"Depression and markers of inflammation as predictors of all-cause mortality in heart failure","volume":"57","author":"Mommersteeg","year":"2016","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.biopsych.2025.11.009_bib17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/PSY.0000000000000289","article-title":"The predictive value of depressive symptoms for all-cause mortality: Findings from the PRIME Belfast study examining the role of inflammation and cardiovascular risk markers","volume":"78","author":"Hughes","year":"2016","journal-title":"Psychosom Med"},{"key":"10.1016\/j.biopsych.2025.11.009_bib18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.psyneuen.2018.05.026","article-title":"Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder","volume":"95","author":"Haroon","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.biopsych.2025.11.009_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.31","article-title":"Altered peripheral immune profiles in treatment-resistant depression: Response to ketamine and prediction of treatment outcome","volume":"7","author":"Kiraly","year":"2017","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib20","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/mp.2015.168","article-title":"Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression","volume":"21","author":"Felger","year":"2016","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41386-018-0259-6","article-title":"Moderators for depressed mood and systemic and transcriptional inflammatory responses: A randomized controlled trial of endotoxin","volume":"44","author":"Irwin","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2025.11.009_bib22","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.biopsych.2010.06.010","article-title":"Inflammation-induced anhedonia: Endotoxin reduces ventral striatum responses to reward","volume":"68","author":"Eisenberger","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib23","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.biopsych.2009.03.015","article-title":"Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity","volume":"66","author":"Harrison","year":"2009","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.18","article-title":"Systemic inflammation enhances stimulant-induced striatal dopamine elevation","volume":"7","author":"Petrulli","year":"2017","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.880568","article-title":"Immune system abnormalities in schizophrenia: An integrative view and translational perspectives","volume":"13","author":"Ermakov","year":"2022","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib26","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6","volume":"1813","author":"J\u00fcrgen","year":"2011","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"10.1016\/j.biopsych.2025.11.009_bib27","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1176\/appi.ajp.20250289","article-title":"Advancing an inflammatory subtype of major depression","volume":"182","author":"Miller","year":"2025","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.psyneuen.2017.01.023","article-title":"Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial","volume":"78","author":"Jha","year":"2017","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.biopsych.2025.11.009_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bbi.2017.07.005","article-title":"Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection","volume":"66","author":"Jha","year":"2017","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.biopsych.2025.11.009_bib30","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41573-021-00368-1","article-title":"Immune targets for therapeutic development in depression: Towards precision medicine","volume":"21","author":"Drevets","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.biopsych.2025.11.009_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113896","article-title":"Clinical translation of immunomodulatory therapeutics","volume":"176","author":"Nash","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.biopsych.2025.11.009_bib33","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/s41380-019-0471-8","article-title":"Effects of immunomodulatory drugs on depressive symptoms: A mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders","volume":"25","author":"Wittenberg","year":"2020","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib34","article-title":"Anti-inflammatory medications for the treatment of mental disorders: A scoping review","volume":"26","author":"Fitton","year":"2022","journal-title":"Brain Behav Immun Health"},{"key":"10.1016\/j.biopsych.2025.11.009_bib35","author":"Baune"},{"key":"10.1016\/j.biopsych.2025.11.009_bib36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/2013.jamapsychiatry.4","article-title":"A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers","volume":"70","author":"Raison","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib37","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/jamapsychiatry.2019.0779","article-title":"Efficacy of adjunctive infliximab vs placebo in the treatment of adults with bipolar I\/II depression: A randomized clinical trial","volume":"76","author":"McIntyre","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib38","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.bbi.2020.04.063","article-title":"Efficacy of adjunctive infliximab vs. placebo in the treatment of anhedonia in bipolar I\/II depression","volume":"88","author":"Lee","year":"2020","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.biopsych.2025.11.009_bib39","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bbi.2013.04.004","article-title":"Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression","volume":"31","author":"Mehta","year":"2013","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.biopsych.2025.11.009_bib40","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4088\/JCP.15l09920","article-title":"An open-label, pilot trial of adjunctive tocilizumab in schizophrenia","volume":"77","author":"Miller","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib41","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/npp.2017.258","article-title":"A randomized, double-blind, placebo-controlled clinical trial of tocilizumab, an interleukin-6 receptor antibody, for residual symptoms in schizophrenia","volume":"43","author":"Girgis","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2025.11.009_bib42","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/s41380-024-02751-x","article-title":"A randomized proof-of-mechanism trial of TNF antagonism for motivational deficits and related corticostriatal circuitry in depressed patients with high inflammation","volume":"30","author":"Treadway","year":"2025","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib43","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jpsychires.2022.12.003","article-title":"Rituximab as an adjunctive treatment for schizophrenia spectrum disorder or obsessive\u2013compulsive disorder: Two open-label pilot studies on treatment-resistant patients","volume":"158","author":"Bejerot","year":"2023","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.biopsych.2025.11.009_bib44","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/YIC.0000000000000399","article-title":"Risperidone combination therapy with adalimumab for treatment of chronic schizophrenia: A randomized, double-blind, placebo-controlled clinical trial","volume":"37","author":"Motamed","year":"2022","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.11.009_bib45","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bbi.2023.10.012","article-title":"Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: A randomized control trial","volume":"115","author":"Weickert","year":"2024","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.biopsych.2025.11.009_bib46","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.neuropharm.2011.08.018","article-title":"Depressive-like behavior induced by tumor necrosis factor-\u03b1 in mice","volume":"62","author":"Kaster","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2025.11.009_bib47","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.23nr15243","article-title":"Immune-targeted therapies for depression: Current evidence for antidepressant effects of monoclonal antibodies","volume":"85","author":"Rizk","year":"2024","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib48","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41380-022-01846-7","article-title":"Overexpression of transmembrane TNF\u03b1 in brain endothelial cells induces schizophrenia-relevant behaviors","volume":"28","author":"Yeo","year":"2023","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib49","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bbi.2019.06.043","article-title":"B-cells and schizophrenia: A promising link or a finding lost in translation?","volume":"81","author":"van Mierlo","year":"2019","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.biopsych.2025.11.009_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.120","article-title":"Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes","volume":"2","author":"Sukoff Rizzo","year":"2012","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib51","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.3390\/ijms21062194","article-title":"Role of interleukin-6 in depressive disorder","volume":"21","author":"Ting","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.biopsych.2025.11.009_bib52","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.bbr.2009.04.021","article-title":"Prepulse inhibition and genetic mouse models of schizophrenia","volume":"204","author":"Powell","year":"2009","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.biopsych.2025.11.009_bib53","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.yfrne.2008.10.001","article-title":"Interleukin-1 (IL-1): A central regulator of stress responses","volume":"30","author":"Goshen","year":"2009","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.biopsych.2025.11.009_bib54","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.psychres.2013.12.051","article-title":"Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study","volume":"215","author":"Khodaie-Ardakani","year":"2014","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biopsych.2025.11.009_bib55","article-title":"Sex differences in a double-blind randomized clinical trial with minocycline in treatment-resistant depressed patients: CRP and IL-6 as sex-specific predictors of treatment response","volume":"26","author":"Lombardo","year":"2022","journal-title":"Brain Behav Immun Health"},{"key":"10.1016\/j.biopsych.2025.11.009_bib56","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/WNF.0b013e3181593d45","article-title":"Minocycline as adjunctive therapy for schizophrenia: An open-label study","volume":"31","author":"Miyaoka","year":"2008","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.biopsych.2025.11.009_bib57","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41386-020-00948-6","article-title":"Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: Results from a double-blind randomised clinical trial","volume":"46","author":"Nettis","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2025.11.009_bib58","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1177\/0004867420965697","article-title":"Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials","volume":"55","author":"Zazula","year":"2021","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib59","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pnpbp.2018.04.004","article-title":"Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels","volume":"85","author":"Zhang","year":"2018","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib60","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.4088\/JCP.09l05805blu","article-title":"Minocycline augmentation of pharmacotherapy in obsessive\u2013compulsive disorder: An open-label trial","volume":"71","author":"Rodriguez","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib61","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41598-018-36507-9","article-title":"The antidepressant impact of minocycline in rodents: A systematic review and meta-analysis","volume":"9","author":"Reis","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.biopsych.2025.11.009_bib62","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12974-022-02492-0","article-title":"Microglia in depression: An overview of microglia in the pathogenesis and treatment of depression","volume":"19","author":"Wang","year":"2022","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.biopsych.2025.11.009_bib63","first-page":"493","article-title":"Microglia activation and schizophrenia: Lessons from the effects of minocycline on postnatal neurogenesis, neuronal survival and synaptic pruning","volume":"43","author":"Inta","year":"2017","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2025.11.009_bib64","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.3390\/ijms24065250","article-title":"Minocycline as treatment for psychiatric and neurological conditions: A systematic review and meta-analysis","volume":"24","author":"Panizzutti","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.biopsych.2025.11.009_bib65","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/schbul\/sbaa198","article-title":"Adjunctive aspirin vs placebo in patients with schizophrenia: Results of two randomized controlled trials","volume":"47","author":"Weiser","year":"2021","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2025.11.009_bib66","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jad.2012.03.033","article-title":"Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled study","volume":"141","author":"Abbasi","year":"2012","journal-title":"J Affect Disord"},{"key":"10.1016\/j.biopsych.2025.11.009_bib67","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/da.20589","article-title":"Clinical trial of adjunctive celecoxib treatment in patients with major depression: A double blind and placebo controlled trial","volume":"26","author":"Akhondzadeh","year":"2009","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.biopsych.2025.11.009_bib68","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.schres.2006.11.016","article-title":"Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial","volume":"90","author":"Akhondzadeh","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2025.11.009_bib69","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bdi.12324","article-title":"Celecoxib adjunctive therapy for acute bipolar mania: A randomized, double-blind, placebo-controlled trial","volume":"17","author":"Arabzadeh","year":"2015","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.biopsych.2025.11.009_bib70","doi-asserted-by":"crossref","DOI":"10.5812\/ijpbs.5848","article-title":"Aspirin inclusion in antipsychotic treatment on severity of symptoms in schizophrenia: A Randimized clinical trial","volume":"11","author":"Attari","year":"2016","journal-title":"Iran J Psychiatry Behav Sci"},{"key":"10.1016\/j.biopsych.2025.11.009_bib71","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.euroneuro.2021.07.092","article-title":"No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial","volume":"53","author":"Baune","year":"2021","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2025.11.009_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2018.02.004","article-title":"Plasma C-reactive protein levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment","volume":"102","author":"Edberg","year":"2018","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.biopsych.2025.11.009_bib73","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/YIC.0000000000000356","article-title":"Effects of celecoxib augmentation of antidepressant or anxiolytic treatment on affective symptoms and inflammatory markers in patients with anxiety disorders: Exploratory study","volume":"36","author":"Elnazer","year":"2021","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.11.009_bib74","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4088\/JCP.09m05117yel","article-title":"Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: Results from a randomized, double-blind, placebo-controlled trial","volume":"71","author":"Laan","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib75","first-page":"891","article-title":"A randomized, double-blind, placebo-controlled trial of celecoxib augmentation of sertraline in treatment of drug-naive depressed women: A pilot study","volume":"14","author":"Majd","year":"2015","journal-title":"Iran J Pharm Res"},{"key":"10.1016\/j.biopsych.2025.11.009_bib76","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/sj.mp.4001805","article-title":"The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine","volume":"11","author":"M\u00fcller","year":"2006","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib77","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1176\/appi.ajp.159.6.1029","article-title":"Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia","volume":"159","author":"M\u00fcller","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib78","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.schres.2010.04.015","article-title":"Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment","volume":"121","author":"M\u00fcller","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2025.11.009_bib79","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00406-004-0478-1","article-title":"COX-2 inhibition as a treatment approach in schizophrenia: Immunological considerations and clinical effects of celecoxib add-on therapy","volume":"254","author":"M\u00fcller","year":"2004","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2025.11.009_bib80","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hup.912","article-title":"Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: A double-blind, randomized, placebo-controlled study","volume":"23","author":"Nery","year":"2008","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.11.009_bib81","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.biopsych.2005.02.024","article-title":"Celecoxib augmentation of continuously ill patients with schizophrenia","volume":"57","author":"Rapaport","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib82","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41398-021-01688-x","article-title":"Associations between expression of indoleamine 2, 3-dioxygenase enzyme and inflammatory cytokines in patients with first-episode drug-naive Schizophrenia","volume":"11","author":"Zhang","year":"2021","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.909981","article-title":"Antidepressant effects of NSAIDs in rodent models of depression-A systematic review","volume":"13","author":"Bay-Richter","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.biopsych.2025.11.009_bib84","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18m12200","article-title":"A double-blind, randomized, placebo-controlled study of aspirin and N-acetylcysteine as adjunctive treatments for bipolar depression","volume":"80","author":"Bauer","year":"2018","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib85","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/jnnp-2019-320912","article-title":"Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: A systematic review and meta-analysis of randomised controlled trials","volume":"91","author":"Bai","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2025.116575","article-title":"Targeting of inflammation and prostaglandins by nonsteroidal anti-inflammatory drugs in schizophrenia: A narrative review","volume":"351","author":"Al-Kuraishy","year":"2025","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biopsych.2025.11.009_bib87","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bbi.2020.08.028","article-title":"Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders\u2014A comprehensive systematic review and meta-analysis","volume":"90","author":"Jeppesen","year":"2020","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.biopsych.2025.11.009_bib88","first-page":"S292","article-title":"A double-blind, placebo-controlled, multicenter study of sirukumab as adjunctive treatment to a monoaminergic antidepressant in adults with major depressive disorder","volume":"43","author":"Salvadore","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2025.11.009_bib89","article-title":"Minocycline in major depressive disorder: And overview with considerations on treatment-resistance and comparisons with other psychiatric disorders","volume":"17","author":"Nettis","year":"2021","journal-title":"Brain Behav Immun Health"},{"key":"10.1016\/j.biopsych.2025.11.009_bib90","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.npbr.2018.10.001","article-title":"Reduction in serum IL-1\u03b2, IL-6, and IL-18 levels and Beck Depression Inventory-II score by combined sertraline and ketoprofen administration in major depressive disorder: A clinical trial","volume":"30","author":"Al-Hakeim","year":"2018","journal-title":"Neurol Psychiatry Brain Res"},{"key":"10.1016\/j.biopsych.2025.11.009_bib91","doi-asserted-by":"crossref","first-page":"7393","DOI":"10.1038\/s41380-021-01188-w","article-title":"Association of inflammation with depression and anxiety: Evidence for symptom-specificity and potential causality from UK Biobank and NESDA cohorts","volume":"26","author":"Milaneschi","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib92","author":"McIntyre"},{"key":"10.1016\/j.biopsych.2025.11.009_bib94","author":"Girgis"},{"key":"10.1016\/j.biopsych.2025.11.009_bib95","author":"Simpson"},{"key":"10.1016\/j.biopsych.2025.11.009_bib96","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2215-0366(20)30138-3","article-title":"Minocycline and celecoxib as adjunctive treatments for bipolar depression: A multicentre, factorial design randomised controlled trial","volume":"7","author":"Husain","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib97","author":"Kocsis"},{"key":"10.1016\/j.biopsych.2025.11.009_bib98","author":"Alexopoulos"},{"key":"10.1016\/j.biopsych.2025.11.009_bib99","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41398-017-0073-7","article-title":"Treatment of bipolar depression with minocycline and\/or aspirin: An adaptive, 2\u00d72 double-blind, randomized, placebo-controlled, phase IIA clinical trial","volume":"8","author":"Savitz","year":"2018","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib100","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1177\/0004867417709357","article-title":"Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial","volume":"51","author":"Dean","year":"2017","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib101","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1177\/0269881117724352","article-title":"Minocycline as an adjunct for treatment-resistant depressive symptoms: A pilot randomised placebo-controlled trial","volume":"31","author":"Husain","year":"2017","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.11.009_bib102","author":"Chaudhry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib103","article-title":"Minocycline for the treatment of early-phase schizophrenia","author":"Levkovitz","year":"2008","journal-title":"Shalvata Mental Health Center"},{"key":"10.1016\/j.biopsych.2025.11.009_bib104","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.schres.2014.01.011","article-title":"Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: A double blind, randomized, controlled trial","volume":"153","author":"Liu","year":"2014","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2025.11.009_bib105","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/JCP.0000000000000345","article-title":"Adjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptoms","volume":"35","author":"Kelly","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.11.009_bib106","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2215-0366(18)30345-6","article-title":"The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): A randomised, double-blind, placebo-controlled trial","volume":"5","author":"Deakin","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib107","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.schres.2018.10.023","article-title":"The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial","volume":"206","author":"Weiser","year":"2019","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2025.11.009_bib108","author":"Cotes"},{"key":"10.1016\/j.biopsych.2025.11.009_bib109","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2174\/1871523013666140804225608","article-title":"Augmentation of citalopram with aspirin for treating major depressive disorder, a double blind randomized placebo controlled clinical trial","volume":"13","author":"Ghanizadeh","year":"2014","journal-title":"Antiinflamm Antiallergy Agents Med Chem"},{"key":"10.1016\/j.biopsych.2025.11.009_bib110","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jad.2019.10.021","article-title":"Modulation of the inflammatory response benefits treatment-resistant bipolar depression: A randomized clinical trial","volume":"261","author":"Halaris","year":"2020","journal-title":"J Affect Disord"},{"key":"10.1016\/j.biopsych.2025.11.009_bib111","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41398-022-01883-4","article-title":"No increase in inflammation in late-life major depression screened to exclude physical illness","volume":"12","author":"Luning Prak","year":"2022","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.009_bib112","article-title":"Aspirin in young psychotic patients. Clinic for Psychiatric Disorders","author":"Pavi\u0107evi\u0107","year":"2024","journal-title":"Dr Laza Lazarevic"},{"key":"10.1016\/j.biopsych.2025.11.009_bib113","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/s41386-023-01760-8","article-title":"A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-na\u00efve first episode schizophrenia: Pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms","volume":"49","author":"Wang","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2025.11.009_bib114","author":"Okusaga"},{"key":"10.1016\/j.biopsych.2025.11.009_bib115","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/JCP.0000000000001253","article-title":"Anti-inflammatory combination therapy for the treatment of schizophrenia","volume":"40","author":"Buchanan","year":"2020","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.11.009_bib116","author":"Fan"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322325016361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322325016361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T20:52:32Z","timestamp":1778705552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322325016361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":114,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0006322325016361"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2025.11.009","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lessons From Clinical Trials of Immunomodulatory Drugs in Psychiatric Disorders","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2025.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}]}}